111 Capital’s Dyne Therapeutics DYN Stock Holding History

111 Capital’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-15,458	Closed	-$147K	–	530
2025 Q2	$147K	Buy	+15,458	New	+$170K	0.03%	467

Other funds holding DYN

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

111 Capital's DYN Position: Q3 2025 in Review

111 Capital sold out of Dyne Therapeutics (DYN) in Q3 2025, closing a stake of 15,458 shares — an estimated $147K sold.

111 Capital first reported a position in DYN in Q2 2025 and held it in 1 quarter. The position peaked at $147K in Q2 2025. 207 funds tracked by Wall St. Rank hold DYN as of Q3 2025.

111 Capital reported no remaining Dyne Therapeutics position as of Q3 2025 after selling out during the quarter.
111 Capital sold 15,458 Dyne Therapeutics shares in Q3 2025, an estimated $147K.
111 Capital first reported a position in Dyne Therapeutics in Q2 2025 and held it in 1 quarter.
111 Capital's Dyne Therapeutics position peaked at $147K in Q2 2025.
207 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2025.

Based on 111 Capital's 13F filing for Q3 2025, filed 12 Nov 2025.